Signs and symptoms of ocular surface status in glaucoma patients switched from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: A 6-month efficacy and tolerability, multicenter, open-label prospective study

Gemma Caterina Maria Rossi, Carmine Tinelli, Gian Maria Pasinetti, Marina Fusetti, Claudio Pallavicini, Massimo Stringa, Sauro Vacchi, Francesco Stringa, Paolo Emilio Bianchi

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To examine the impact of switching glaucoma patients from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination (Brinz/Tim FC) on quality of life and on ocular surface status; to assess efficacy after the switch. Methods: 6-month, multicenter, open-label, prospective, switch study in 119 early to moderate glaucoma patients. Intraocular pressure (IOP), tear film break-up time (TF-BUT), fluorescein staining and Glaucoma Symptom Scale (GSS) questionnaire were recorded at baseline and after 6 months. Results: Median (interquartile range) IOP significantly decreased from 20 to 16 mmHg, independent of sex and age. Most patients (95.8%) reached an IOP <18 mmHg. TF-BUT improved, with a negative weak correlation to age at baseline and at 6 months. The percentage of patients with no fluorescein staining improved. The quality of life recorded by GSS also improved, being related both to age and corneal staining. Conclusion: Brinz/Tim FC is effective and well tolerated. In this study, patients switched to Brinz/Tim FC obtained further reduction in IOP with no effects on ocular surface status and improved quality of life perception: a better quality of life could determine a better adherence to prescribed therapy.

Original languageEnglish
Pages (from-to)685-690
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number5
DOIs
Publication statusPublished - Apr 2011

Keywords

  • brinzolamide/timolol fixed combination
  • corneal staining
  • glaucoma
  • glaucoma symptom scale
  • ocular surface status
  • quality of life
  • switch
  • TF-BUT
  • tolerability

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Fingerprint Dive into the research topics of 'Signs and symptoms of ocular surface status in glaucoma patients switched from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: A 6-month efficacy and tolerability, multicenter, open-label prospective study'. Together they form a unique fingerprint.

Cite this